Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Roche,Vemurafenib,"Melanoma, Stage IIIC/IV with BRAF V600 mutation",Vemurafenib (Zelboraf),Recommended for decline,Community and Hospital,Oncology Agents and Immunosuppressants
